Previous studies have shown that sorafenib, lapatinib, 5-FU, bortezomib, docetaxel, vinorelbine, and other anticancer drugs could induce eIF2α phosphorylation-dependent SGs, which promote the survival of cancer cells [1,26,27,28,29,30,31,32]. The gene discussed is EIF2A; the disease is cancer.